Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2023-11-09 5:24 pm Unchanged | 2023-08-11 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 4,328,883 8.400% | 0 (Unchanged) | Filing History |
2023-02-09 4:19 pm Sale | 2022-12-31 | 13G | Century Therapeutics, Inc. IPSC | Versant Venture Capital VI L.P. | 11,452,014 19.400% | -914,800![]() (-7.40%) | Filing History |
2023-01-13 4:09 pm Sale | 2023-01-03 | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 0 0.000% | -2,236,888![]() (Position Closed) | Filing History |
2022-05-09 5:26 pm Purchase | 2022-04-29 | 13D | Tempest Therapeutics, Inc. TPST | Versant Venture Capital VI L.P. | 162,973 20.500% | 72,321![]() (+79.78%) | Filing History |
2022-02-10 8:39 pm Purchase | 2021-12-31 | 13G | Century Therapeutics, Inc. IPSC | Versant Venture Capital VI L.P. | 12,366,814 22.600% | 12,366,814![]() (New Position) | Filing History |
2022-02-10 7:41 pm Purchase | 2021-12-31 | 13G | Tempest Therapeutics, Inc. TPST | Versant Venture Capital VI L.P. | 90,652 17.100% | 90,652![]() (New Position) | Filing History |
2022-01-13 4:34 pm Unchanged | 2022-01-05 | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.500% | 0 (Unchanged) | Filing History |
2021-10-27 4:32 pm Unchanged | 2021-10-18 | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.600% | 0 (Unchanged) | Filing History |
2021-07-09 4:43 pm Purchase | 2021-06-29 | 13D | Graphite Bio, Inc. GRPH | Versant Venture Capital VI L.P. | 2,101,200 26.300% | 2,101,200![]() (New Position) | Filing History |
2021-07-08 4:31 pm Purchase | 2021-06-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI L.P. | 6,799,115 15.300% | 6,799,115![]() (New Position) | Filing History |
2021-06-21 4:44 pm Sale | 2021-06-11 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI L.P. | 58,317 3.800% | -19,439![]() (-25.00%) | Filing History |
2021-05-24 4:27 pm Unchanged | 2021-05-12 | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.600% | 0 (Unchanged) | Filing History |
2021-05-03 4:57 pm Sale | 2021-04-26 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI L.P. | 77,757 5.100% | -19,439![]() (-20.00%) | Filing History |
2021-04-08 4:31 pm Purchase | 2021-03-29 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 3,407,157 13.400% | 3,407,157![]() (New Position) | Filing History |
2021-04-05 4:33 pm Unchanged | 2021-03-26 | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.600% | 0 (Unchanged) | Filing History |
2021-03-01 5:16 pm Sale | 2021-02-17 | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.600% | -325,000![]() (-12.69%) | Filing History |
2021-02-12 8:41 pm Sale | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Versant Venture Capital VI L.P. | 777,727 2.200% | -2,878,858![]() (-78.73%) | Filing History |
2020-12-03 4:47 pm Sale | 2020-11-23 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 4,328,883 12.000% | -1,031,634![]() (-19.25%) | Filing History |
2020-11-20 5:32 pm Sale | 2020-11-11 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 5,360,517 14.900% | -980,734![]() (-15.47%) | Filing History |
2020-10-30 4:25 pm Purchase | 2020-10-20 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI L.P. | 97,196 7.200% | 97,196![]() (New Position) | Filing History |